Compact Diagnostic Scope HiberGene is a Dublin-based private company focusing on rapid, cost-effective molecular diagnostics using LAMP technology, with a small team (11-50 employees) and revenue under $1M, indicating a high-potential niche in near-patient and laboratory settings for infectious disease testing.

Expanded Product Line With an expanding HG product line including COVID-19, Meningococcus, GBS, C. difficile, and Mycoplasma pneumoniae tests, there are multiple cross-sell opportunities across hospital laboratories, clinics, and public health labs seeking rapid results on a single platform.

Regulatory Momentum Recent CE Markings for combined COVID-19 and Flu tests demonstrate regulatory traction and market readiness in Europe, suggesting opportunities to approach EU hospitals and public health authorities with validated, fast-turnaround solutions.

Strategic Partnerships Past collaborations with academic and hospital partners (QUB, Genoa hospital) and EU funding indicate a proven pathway for co-development and validation projects, presenting avenues for joint bids and funded deployments.

Global Market Potential Despite modest revenue, the technology stack and near-patient applicability position HiberGene to scale via diagnostic networks, with target opportunities in disease surveillance, maternity health (GBS), and point-of-care testing in diverse clinical environments.